{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T14:54:21Z","timestamp":1785596061491,"version":"3.56.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T00:00:00Z","timestamp":1716422400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T00:00:00Z","timestamp":1716422400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100007132","name":"Otsuka Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007132","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100030831","name":"Novartis Japan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100030831","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004948","name":"Astellas Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004948","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Asahikasei Pharma Japan"},{"DOI":"10.13039\/501100013170","name":"Ono Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013170","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1007\/s00280-024-04673-5","type":"journal-article","created":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T17:01:48Z","timestamp":1716483708000},"page":"285-296","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Overexposure to venetoclax is associated with prolonged-duration of neutropenia during venetoclax and azacitidine therapy in Japanese patients with acute myeloid leukemia"],"prefix":"10.1007","volume":"94","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8058-7301","authenticated-orcid":false,"given":"Takahiro","family":"Kobayashi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Honami","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masatomo","family":"Miura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yayoi","family":"Fukushi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wataru","family":"Kuroki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumiko","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuaki","family":"Teshima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naohito","family":"Fujishima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isuzu","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Kameoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoto","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,23]]},"reference":[{"issue":"7","key":"4673_CR1","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1007\/s00277-015-2351-x","volume":"94","author":"BC Medeiros","year":"2015","unstructured":"Medeiros BC, Satram-Hoang S, Hurst D, Hoang KQ, Momin F, Reyes C (2015) Big data analysis of treatment patterns and outcomes among elderly acute myeloid leukemia patients in the United States. Ann Hematol 94(7):1127\u20131138","journal-title":"Ann Hematol"},{"issue":"7","key":"4673_CR2","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH et al (2020) Azacitidine and Venetoclax in previously untreated Acute Myeloid Leukemia. N Engl J Med 383(7):617\u2013629","journal-title":"N Engl J Med"},{"issue":"11","key":"4673_CR3","doi-asserted-by":"publisher","first-page":"E416","DOI":"10.1002\/ajh.26692","volume":"97","author":"KW Pratz","year":"2022","unstructured":"Pratz KW, DiNardo CD, Selleslag D, Li J, Yamamoto K, Konopleva M et al (2022) Postremission Cytopenia management in patients with acute myeloid leukemia treated with venetoclax and azacitidine in VIALE-A. Am J Hematol 97(11):E416\u2013e19","journal-title":"Am J Hematol"},{"issue":"279","key":"4673_CR4","doi-asserted-by":"publisher","first-page":"279ra40","DOI":"10.1126\/scitranslmed.aaa4642","volume":"7","author":"JD Leverson","year":"2015","unstructured":"Leverson JD, Phillips DC, Mitten MJ, Boghaert ER, Diaz D, Tahir SK et al (2015) Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy. Sci Transl Med 7(279):279ra40","journal-title":"Sci Transl Med"},{"issue":"4","key":"4673_CR5","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1513257","volume":"374","author":"AW Roberts","year":"2016","unstructured":"Roberts AW, Davids MS, Pagel JM, Kahl BS, Puvvada SD, Gerecitano JF et al (2016) Targeting BCL2 with Venetoclax in Relapsed Chronic lymphocytic leukemia. N Engl J Med 374(4):311\u2013322","journal-title":"N Engl J Med"},{"issue":"4","key":"4673_CR6","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1002\/cpdd.395","volume":"7","author":"TT Cheung","year":"2018","unstructured":"Cheung TT, Salem AH, Menon RM, Munasinghe WP, Bueno OF, Agarwal SK (2018) Pharmacokinetics of the BCL-2 inhibitor venetoclax in healthy Chinese subjects. Clin Pharmacol Drug Dev 7(4):435\u2013440","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"2","key":"4673_CR7","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1002\/hon.2964","volume":"40","author":"D Brackman","year":"2022","unstructured":"Brackman D, Eckert D, Menon R, Salem AH, Potluri J, Smith BD et al (2022) Venetoclax exposure-efficacy and exposure-safety relationships in patients with treatment-na\u00efve acute myeloid leukemia who are ineligible for intensive chemotherapy. Hematol Oncol 40(2):269\u2013279","journal-title":"Hematol Oncol"},{"issue":"24","key":"4673_CR8","doi-asserted-by":"publisher","first-page":"4642","DOI":"10.1200\/JCO.2003.04.036","volume":"21","author":"BD Cheson","year":"2003","unstructured":"Cheson BD, Bennett JM, Kopecky KJ, B\u00fcchner T, Willman CL, Estey EH et al (2003) Revised recommendations of the International Working Group for Diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in Acute myeloid leukemia. J Clin Oncol 21(24):4642\u20134649","journal-title":"J Clin Oncol"},{"issue":"12","key":"4673_CR9","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H et al (2022) Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood 140(12):1345\u20131377","journal-title":"Blood"},{"key":"4673_CR10","doi-asserted-by":"crossref","unstructured":"Fukuda N, Kobayashi T, Sato H, Akamine Y, Takahashi N, Miura M (2022) Quantitation of Venetoclax in Human plasma by high-performance liquid chromatography with Ultraviolet Detection. J Chromatogr Sci. Oct 31","DOI":"10.1093\/chromsci\/bmac080"},{"issue":"11","key":"4673_CR11","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/jhg.2010.98","volume":"55","author":"N Takahashi","year":"2010","unstructured":"Takahashi N, Miura M, Scott SA, Kagaya H, Kameoka Y, Tagawa H et al (2010) Influence of CYP3A5 and drug transporter polymorphisms on imatinib trough concentration and clinical response among patients with chronic phase chronic myeloid leukemia. J Hum Genet 55(11):731\u2013737","journal-title":"J Hum Genet"},{"issue":"6","key":"4673_CR12","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s12032-019-1280-2","volume":"36","author":"T Kobayashi","year":"2019","unstructured":"Kobayashi T, Miura M, Abumiya M, Akamine Y, Ito F, Takahashi N (2019) Influence of ABCB1 polymorphisms on the pharmacokinetics and toxicity of lenalidomide in patients with multiple myeloma. Med Oncol 36(6):55","journal-title":"Med Oncol"},{"issue":"3","key":"4673_CR13","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y (2013) Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transpl 48(3):452\u2013458","journal-title":"Bone Marrow Transpl"},{"issue":"4","key":"4673_CR14","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1002\/hon.2646","volume":"37","author":"S Agarwal","year":"2019","unstructured":"Agarwal S, Gopalakrishnan S, Mensing S, Potluri J, Hayslip J, Kirschbrown W et al (2019) Optimizing venetoclax dose in combination with low intensive therapies in elderly patients with newly diagnosed acute myeloid leukemia: an exposure-response analysis. Hematol Oncol 37(4):464\u2013473","journal-title":"Hematol Oncol"},{"issue":"1","key":"4673_CR15","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1093\/jjco\/hyab170","volume":"52","author":"K Yamamoto","year":"2022","unstructured":"Yamamoto K, Shinagawa A, DiNardo CD, Pratz KW, Ishizawa K, Miyamoto T et al (2022) Venetoclax plus azacitidine in Japanese patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy. Jpn J Clin Oncol 52(1):29\u201338","journal-title":"Jpn J Clin Oncol"},{"issue":"6","key":"4673_CR16","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1093\/jjco\/hyab018","volume":"51","author":"S Taniguchi","year":"2021","unstructured":"Taniguchi S, Yamauchi T, Choi I, Fukuhara N, Potluri J, Salem AH et al (2021) Venetoclax in combination with azacitidine in Japanese patients with acute myeloid leukaemia: phase 1 trial findings. Jpn J Clin Oncol 51(6):857\u2013864","journal-title":"Jpn J Clin Oncol"},{"issue":"5","key":"4673_CR17","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1208\/s12248-016-9927-9","volume":"18","author":"AK Jones","year":"2016","unstructured":"Jones AK, Freise KJ, Agarwal SK, Humerickhouse RA, Wong SL, Salem AH (2016) Clinical predictors of Venetoclax Pharmacokinetics in Chronic lymphocytic leukemia and Non-hodgkin\u2019s Lymphoma patients: a Pooled Population Pharmacokinetic Analysis. Aaps j 18(5):1192\u20131202","journal-title":"Aaps j"},{"issue":"11","key":"4673_CR18","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1002\/jcph.730","volume":"56","author":"SK Agarwal","year":"2016","unstructured":"Agarwal SK, Hu B, Chien D, Wong SL, Salem AH (2016) Evaluation of Rifampin\u2019s Transporter Inhibitory and CYP3A Inductive effects on the pharmacokinetics of Venetoclax, a BCL-2 inhibitor: results of a single- and multiple-dose study. J Clin Pharmacol 56(11):1335\u20131343","journal-title":"J Clin Pharmacol"},{"issue":"2","key":"4673_CR19","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.clinthera.2017.01.003","volume":"39","author":"SK Agarwal","year":"2017","unstructured":"Agarwal SK, DiNardo CD, Potluri J, Dunbar M, Kantarjian HM, Humerickhouse RA et al (2017) Management of Venetoclax-Posaconazole Interaction in Acute myeloid leukemia patients: evaluation of dose adjustments. Clin Ther 39(2):359\u2013367","journal-title":"Clin Ther"},{"issue":"4","key":"4673_CR20","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1111\/bcp.13175","volume":"83","author":"SK Agarwal","year":"2017","unstructured":"Agarwal SK, Salem AH, Danilov AV, Hu B, Puvvada S, Gutierrez M et al (2017) Effect of ketoconazole, a strong CYP3A inhibitor, on the pharmacokinetics of venetoclax, a BCL-2 inhibitor, in patients with non-hodgkin lymphoma. Br J Clin Pharmacol 83(4):846\u2013854","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"4673_CR21","doi-asserted-by":"publisher","first-page":"666","DOI":"10.4149\/neo_2013_085","volume":"60","author":"SV Mehta","year":"2013","unstructured":"Mehta SV, Shukla SN, Vora HH (2013) Overexpression of Bcl2 protein predicts chemoresistance in acute myeloid leukemia: its correlation with FLT3. Neoplasma 60(6):666\u2013675","journal-title":"Neoplasma"},{"issue":"11","key":"4673_CR22","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1093\/oncolo\/oyac135","volume":"27","author":"P Vachhani","year":"2022","unstructured":"Vachhani P, Flahavan EM, Xu T, Ma E, Montez M, Gershon A et al (2022) Venetoclax and Hypomethylating agents as First-line treatment in newly diagnosed patients with AML in a Predominately Community setting in the US. Oncologist 27(11):907\u2013918","journal-title":"Oncologist"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-024-04673-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-024-04673-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-024-04673-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T09:05:16Z","timestamp":1726045516000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-024-04673-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,23]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["4673"],"URL":"https:\/\/doi.org\/10.1007\/s00280-024-04673-5","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,23]]},"assertion":[{"value":"22 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The multicenter prospective observational study was conducted in Akita prefecture, Japan. This study enrolled patients with AML who were judged ineligible for intensive chemotherapy by the attending physician. This study was conducted in accordance with the 1964 Helsinki Declaration and approved by the Ethics Committee of Akita University (August 6, 2021\/No. 2696). Written informed consent was obtained from all participants before enrollment.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and informed consent"}},{"value":"Naoto Takahashi received honoraria from Otsuka, Novartis, and received research funding from Otsuka, Novartis, Astellas, Asahikasei Pharma, and Ono Pharmaceutical.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}}]}}